Patent Daily RSS
Twitter Guna
- Access the Bayer’s appeal - bit.ly/Lj9RMP 6 days ago
- Bayer seeks to stay the operation of the CL order - bit.ly/JBAlIS 6 days ago
- USPTO Offers Patent Applicants Option to Supplement Disclosure of Prior Art After Paying Issue Fee - bit.ly/Ju5BYd 1 week ago
- Piramal Healthcare to buy US firm to boost R&D - bit.ly/MiVA1V 1 week ago
- Financial challenges, novel drug devpt pressures to hamper India’s R&D growth: Expert - bit.ly/JHsWnw 1 week ago
- Biotech body criticises Bayer on cancer drug - bit.ly/J5DEpF 1 week ago
- India drugs inquiry could prompt new U.S. scrutiny - reut.rs/JDVT5y 1 week ago
- Cipla breached patent rights by slashing cancer drug price: Bayer - bit.ly/JyCBys 2 weeks ago
- No pharma application pending for compulsory licence: Govt - bit.ly/K3OUQy 2 weeks ago
- India’s patent protection regime to be key issue in talks with US - bit.ly/Jfhluh 2 weeks ago
Monthly Archives: June 2011
India: Varenacline Patent revoked
Varenaciline is marketed by Pfizer world wide as Chandix or Champix. Varenaciline is marketed as tartarate salt form, this salt form is protected by US patent 6890927 and its indian equivalent is 204091 (863/MUMNP/2003). This ’091 patent is opposed by Dr … Continue reading
Posted in Patent case
Tagged 204091, 863/MUMNP/2003, Champix, Chandix, Dr Reddy's, pfizer
Leave a comment
Palonosetron-Opposition-India
A new pre grant opposition decision is published by patent office which is related to palonosetron. Application No: 1024/MUMNP/2005, Assignee: Helsinn Healthcare, Title: “Use of palonosetron treating postoperative nausea and vomiting“. This application is opposed by glenmark and Sun pharma. This … Continue reading
Posted in Patent case
Tagged 1024/MUMNP/2005, 25(1), 951/MUMNP/2005, Glenmark, opposition, Palonosetron, Sun Pharma
Leave a comment
Deferacirox-composition-pregrant oppoisition-india
A new pre grant opposition decision is uploaded in IPO site. Application NO: 593/CHENP/2005 is assigned to Novartis and Titled “Dispersible tablets comprising deferacirox”. This application is opposed by Cipla under 25(1). This application is refused under lack of inventive … Continue reading
Erlotinib-divisional-2018/CHE/2006-India
We aware that Erlotinib product patent is granted in India as 196774 (537/DEL/1996) and is is subject of many patent infringement cases filed at Delhi high court. Applicant has a divisional application (2018/CHE/2006) of ’774 patent, which is pending at IPO Chennai. … Continue reading
EPO revokes Esomeprazole patent
[WSJ] [Bloomberg] [Pharmaletter] EPO last Friday revokes EP1020461, which covers magnesium salt of Esomeprazole and it is divisional patent of EP0652872 (product patent). ’461 patent revocation status not yet updated in European patent register. ’461 patent was opposed by many companies including Teva, Hexal, Lupin etc. … Continue reading
India: New-Post Grant Oppositions-Published
1) An opposition under Sec.25(2) has been filed by M/s. Cipla Limited, Mumbai, India on 18th April, 2011 in respect of Patent No.242347 (1702/KOLNP/2006) in the name of M/s. Meda Pharma GmbH & Co, KG, Germany – Combination of R, R- … Continue reading
Posted in Daily interesting IP news, Patent case
Tagged 1702/KOLNP/2006, 239841, 242347, 750/KOLNP/2004, opposition
Leave a comment